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A B S T R A C T
Background: Cirrhosis has been shown to be associated with left ventricular (LV) myocardial dysfunction,
but studies of right ventricular (RV) function in cirrhotic patients compared with controls are scarce.
Limited studies have prospectively evaluated the progression of myocardial function in patients with
cirrhosis and assessed changes in cardiac function following liver transplantation (LTx). So the aim of the
study was to evaluate biventricular myocardial function in cirrhotic patients and its alteration with or
without liver transplantation.
Methods: A total of 103 patients with cirrhosis (age 55  7 years, male 75%) were recruited. Conventional
and 2-dimensional speckle tracking echocardiography was performed to determine the presence of LV and
RV (biventricular) dysfunction. For comparison, 48 matched control subjects were included. Follow-up
echocardiography was performed in 41 patients following LTx and in 26 patients who did not undergo LTx.
Results: Patients with cirrhosis had biventricular dilatation, increased LV mass, impaired LV diastolic
function, and biventricular systolic strain compared with controls. Following LTx, cirrhotic patients had
reduced biventricular dilatation, a smaller LV mass, and improved biventricular systolic strain after a
mean duration of 18.2  6.6 months. Patients who did not undergo LTx had a further increase in LV mass but
no signiﬁcant change in biventricular dimensions or systolic strain (mean duration of 20.4  8.3 months).
Conclusions: The present study demonstrates that patients with cirrhosis had biventricular dilatation
and impaired biventricular systolic strain compared with controls. Following LTx, biventricular
dilatation reduced and biventricular systolic strain improved. In contrast, patients who did not undergo
LTx experienced a further increase in LV mass.
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Patients with cirrhosis have been shown to have myocardial
dysfunction: a distinct entity termed cirrhotic cardiomyopathy has
been attributed to this phenomenon [1,2]. Previous studies using
echocardiography have demonstrated that patients with cirrhosis
have impaired left ventricular (LV) diastolic function [3,4]. With* Corresponding authors at: Cardiology Division, Department of Medicine, The
University of Hong Kong, Room 1929B/K1931, Block K, Queen Mary Hospital, Hong
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0914-5087/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsthe use of advanced 2-dimensional (2D) speckle tracking derived
strain analysis that enables detection of subtle myocardial
dysfunction, a recent study has further shown that patients with
cirrhosis have impaired LV myocardial contractility [5]. Nonethe-
less these studies have been cross-sectional and the focus was on
degree of LV dysfunction in cirrhotic compared with non-cirrhotic
subjects.
Recently, right ventricular (RV) function has been shown to be
superior to LV function in the prediction of adverse clinical
outcome in patients with cirrhosis who undergo liver transplanta-
tion (LTx) [6]. Nonetheless studies of RV function in these patients
compared with controls are scarce. Further, only limited studies
have prospectively evaluated the altered myocardial function in
patients with cirrhosis and assessed the changes following LTx reserved.
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and RV (biventricular) function in cirrhotic patients with controls
and prospectively evaluate the difference in progression of
biventricular function in cirrhotic patients with and without LTx.
Patients and methods
Study population
From January 2011 to August 2013, a total of 103 consecutive
Chinese patients with cirrhosis, aged over 18 and referred to the
Department of Surgery at Queen Mary Hospital (the only center in
Hong Kong) for LTx were recruited. Patients with any one of the
following were excluded: documented history of cardiovascular
disease including coronary artery disease, myocardial infarction,
stroke or peripheral vascular disease, acute liver failure, and LTx
not related to liver cirrhosis. Patients with clinical and echocar-
diographic features of hepato-pulmonary syndrome and pulmo-
nary hypertension were also excluded. For comparison, 48 control
subjects recruited from a health screening program organized by
the Cardiology Division, Department of Medicine, The University of
Hong Kong, were matched with patients for age, sex, body mass
index (BMI), and cardiovascular risk factors.
The study was approved by the local institutional ethics board
and all subjects gave written informed consent.
Study protocols
Data on baseline demographics and clinical characteristics, and
blood sampling were obtained prospectively on the same day in all
study subjects after overnight fasting. BMI and conventional
cardiovascular risk factors such as history of diabetes mellitus
(deﬁned as a serum fasting glucose 7.1 mmol/L or prescription of
anti-hyperglycemic medication), and hypertension (deﬁned as
either resting systolic or diastolic blood pressure 140/90 mmHg
on two occasions or prescription of antihypertensive medication)
were documented. The use of medications, including beta blocker,
calcium channel blocker, angiotensin-converting enzyme inhibi-
tors/angiotensin receptor blockers, and diuretics were recorded in
patients. Clinical status was assessed by the Child-Pugh score and
the model for end-stage liver disease (MELD) score.
Conventional echocardiography
All patients with cirrhosis and controls were imaged in the left
lateral decubitus position using a commercially available echo-
cardiography system (Vingmed Vivid 7, General Electric Vingmed
Ultrasound, Milwaukee, WI, USA). A 3.5-MHz transducer was used
to obtain images that were digitally stored in cine-loop format
(3 cardiac cycles). Ofﬂine analysis was performed using EchoPAC
version 108.1.5 (General Electric – Vingmed, Horten, Norway). The
LV end-diastolic septal and posterior wall thickness, LV dimen-
sions, volumes, and ejection fraction were measured according to
the current recommendations [9]. LV mass was calculated using
Devereux’s Formula [10]. Evaluation of LV diastolic function was
based on the pulsed-wave Doppler of mitral valve inﬂow,
measuring peak early diastolic velocity (E), peak late (A) diastolic
velocity, and E/A ratio. Using tissue Doppler imaging, the early
diastolic velocity (E0) was measured at the level of the LV basal
lateral segment. In addition, E/E0 ratio was calculated as an
estimation of LV ﬁlling pressure [11]. LV diastolic dysfunction was
therefore categorized as previously described: normal; mild,
deﬁned as LV impaired relaxation without evidence of increased
ﬁlling pressure; moderate, deﬁned as LV impaired relaxation
associated with moderate elevation of ﬁlling pressure or pseudo-
normal ﬁlling; and severe, deﬁned as restrictive LV ﬁlling [11].Right ventricular end-diastolic area (RVEDA) and right ventric-
ular end-systolic area (RVESA) were measured by manually tracing
the RV endocardial border on the apical 4-chamber view; care was
taken to obtain a true non-foreshortened view oriented to obtain
the maximum RV dimension. The right ventricular fractional area
change (RVFAC) was calculated using the following equation:
(RVEDA  RVESA)/RVEDA  100% [9], with a lower reference valve
for normal RV systolic function of 35%. Tricuspid annular plane
systolic excursion (TAPSE) was measured from the apical 4-
chamber view: an M-mode cursor was placed through the
tricuspid annulus and the displacement of the base of the RV
free wall along the cursor from end-diastole and end-systole was
measured, with a lower reference value for impaired RV systolic
function of 1.6 cm. Finally, right ventricular systolic pressure
(RVSP) was determined from peak tricuspid regurgitation velocity
by continuous-wave Doppler using simpliﬁed Bernoulli equation
and combining this value with an estimate of the right atrial
pressure (RAP): RVSP = 4(V)2 + RAP. For conventional echocardi-
ography parameters, RV systolic function was quantiﬁed with
RVFAC and TAPSE.
Two-dimensional speckle tracking strain analysis
Two-dimensional speckle tracking strain analysis is an ad-
vanced imaging technique that provides detailed assessment of
myocardial deformation by tracking natural acoustic markers
(speckles) on a frame-to-frame basis within the cardiac cycle. The
speckles are detected on the standard gray-scale 2D images and are
distributed evenly within the myocardium.
Myocardial systolic strain of the LV can be assessed in three
orthogonal directions: longitudinal strain, circumferential strain,
and radial strain. The detailed measurement of LV systolic strain
was determined from the 3 apical (2-, 3-, and 4-chamber) views
and has been described in detail [12,13]. Global longitudinal and
circumferential strains are expressed as negative values, and a
lower strain is represented by a less negative value. Global radial
strain is expressed as a positive value, and a lower value indicates
lower strain.
The measurement of RV global longitudinal systolic strain using
2D speckle tracking analysis has been described previously
[14,15]. Brieﬂy, from the apical 4-chamber view, a region of
interest (ROI) was manually traced along the endocardial border of
the RV free wall and septal wall, and the width was set to match
wall thickness. The tracked ROI was visually checked and adjusted
if necessary and the RV global longitudinal strain calculated
(Fig. 1). RV longitudinal strain is expressed as a negative value: a
lower strain is represented by a smaller negative value.
Follow-up echocardiography
During the study period, 41 patients underwent LTx and a
repeat echocardiography was performed after a mean duration of
18.2  6.6 months following LTx. A total of 62 patients remained on
the waiting list for LTx; 14 patients refused a follow-up echocardiog-
raphy evaluation and 22 patients died during the study period.
Accordingly, 26 patients who did not receive LTx underwent a follow-
up echocardiogram at 20.4  8.3 months as well as baseline
echocardiography.
Statistical analysis
Data are expressed as mean  standard deviation for continuous
variables and frequencies or proportions for categorical variables.
Continuous demographic variables of the two groups were compared
using independent sample Student’s t test. Categorical demographic
variables were compared using Pearson Chi-square test or the Fisher’s
Fig. 1. An example of right ventricle (RV) systolic strain at longitudinal direction measured by 2-dimensional speckle tracking analysis from the apical 4-chamber view. Each
color denotes a regional segmental strain (a total of 6 segments) and the RV systolic strain is calculated as the average value for peak strain of the 6 segments. The white arrow
denotes the directions of longitudinal strain.
Table 2
Clinical characteristics of patients with and without liver transplantation (LTx).
Patients with
LTx (n = 41)
Patients
without
LTx (n = 26)
p
Age (years) 54.9  7.7 54.1  8.2 0.69
Male, n (%) 30 (71.4) 19 (73.1) 0.99
Etiology
Alcohol, n (%) 6 (14.6) 3 (11.5) 0.50
Viral, n (%) 30 (73.2) 17 (65.4)
Other causes, n (%) 5 (12.2) 6 (23.1)
Child-Pugh Grade
A 7 (17.1) 12 (46.2) <0.01
B 11 (26.8) 10 (38.5)
C 23 (56.1) 4 (15.3)
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Comparison of changes for those who underwent LTx (pre-LTx and
post-LTx echocardiography) and those who did not (baseline and
follow-up echocardiography) were performed by paired Student t
tests. All statistical analyses were performed using the statistical
package SPSS for windows (Version 18.0, SPSS, Chicago, IL, USA). All
p-values reported are 2-sided for consistency. A p-value <0.05 was
considered statistically signiﬁcant.
Results
Clinical characteristics
The baseline characteristics of patients with cirrhosis and
controls are shown in Table 1. The age, gender, BMI, and the
prevalence of hypertension, diabetes, and smoker status were
similar between the two groups. Nonetheless patients with
cirrhosis had lower systolic blood pressure, diastolic blood
pressure, and higher heart rate than controls (Table 1).
The majority of patients were male and in over 60% of cases
cirrhosis was due to viral hepatitis. Up to three quarters of patients
had a Child-Pugh grade B or higher degree of cirrhosis. For those
who underwent a second echocardiogram, patients who had
undergone LTx had worse Child-Pugh grade, higher MELD score,
bilirubin, international normalized ratio level, and lower albumin
level than those without LTx (Table 2). The age, gender, etiology ofTable 1
Clinical characteristics of patients with cirrhosis and controls.
Cirrhosis
(n = 103)
Controls
(n = 48)
p
Age (years) 54.9  7.3 53.5  7.9 0.28
Male, n (%) 77 (74.8) 32 (66.7) 0.30
Systolic blood pressure (mmHg) 118.3  17.0 127.3  12.1 0.02
Diastolic blood pressure (mmHg) 67.3  11.2 84.0  8.8 <0.01
Heart rate (beats/min) 70.0  14.1 62.9  9.3 <0.01
Body mass index (kg/m2) 24.7  4.4 23.5  2.5 0.10
Hypertension, n (%) 26 (25.2) 7 (14.5) 0.14
Diabetes mellitus, n (%) 21 (20.4) 5 (10.4) 0.13
Smoker, n (%) 12 (11.7) 8 (16.7) 0.40
Except where indicated otherwise, values are the mean  SD or n (%).cirrhosis, creatinine level, BMI, the prevalence of hypertension,
diabetes, and current smoking were nonetheless similar between
the two groups (Table 2).
Biventricular echocardiographic parameters in patients and controls
Comparison of echocardiographic parameters in patients with
cirrhosis and controls is shown in Table 3. Patients with cirrhosis
had a larger LV dimension, increased LV end-diastolic septal
thickness, and greater LV mass. The prevalence of diastolic
dysfunction and E/E0 ratio was also larger in patients withMELD score 21.3  8.9 12.2  5.6 <0.01
Bilirubin (mg/dl) 225.5  231.0 60.2  100.0 <0.01
Albumin (g/dl) 31.9  7.0 35.6  6.8 0.04
Creatinine (mg/dl) 87.6  37.5 90.3  28.5 0.76
International normalized ratio 1.7  0.5 1.3  0.3 <0.01
Body mass index (kg/m2) 24.1  4.3 24.9  5.9 0.50
Hypertension, n (%) 10 (24.4) 7 (26.9) 0.82
Diabetes mellitus, n (%) 7 (17.1) 7 (26.9) 0.33
Smoker, n (%) 3 (7.3) 5 (19.2) 0.14
Medications, n (%)
Beta blocker 13 (31.7) 11 (42.3) 0.26
Calcium channel blocker 13 (31.7) 7 (26.9) 0.44
ACEI/ARB 3 (7.3) 2 (7.7) 0.65
Diuretics 14 (34.1) 11 (42.3) 0.50
Except where indicated otherwise, values are the mean  SD or n (%). ACEI,
angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker;
MELD, model for end stage liver disease.
Table 3
Echocardiography parameters in patients with cirrhosis and controls.
Cirrhosis
(n = 103)
Controls
(n = 48)
p
LV conventional parameters
LV end-diastolic septal thickness (cm) 1.1  0.2 1.0  0.1 <0.01
LV end-diastolic diameter (cm) 4.7  0.7 4.5  0.4 0.02
LV end-diastolic posterior
wall thickness (cm)
1.0  0.2 1.0  0.1 0.73
LV mass (g) 208.5  57.5 175.6  42.8 <0.01
LV end diastolic volume (ml) 94.0  29.2 74.0  16.0 <0.01
LV end systolic volume (ml) 33.4  12.7 26.5  7.5 <0.01
LV ejection fraction (%) 65.1  4.8 64.1  4.4 0.19
Heart rate (beats/min) 70.0  14.1 62.9  9.3 <0.01
LV diastolic function parameters
E (m/s) 0.84  0.21 0.74  0.14 <0.01
A (m/s) 0.80  0.25 0.64  0.14 <0.01
E/A ratio 1.13  0.42 1.20  0.30 0.22
LV diastolic function, n (%)
Normal 60 (58.3) 35 (72.9) <0.01
Mild 40 (38.8) 13 (27.1)
Moderate 1 (1) 0 (0)
Severe 2 (1.9) 0 (0)
E/e0 – lateral 7.42  2.37 6.35  1.42 <0.01
LV strain analysis
LS (%) 18.6  2.6 20.1  2.8 <0.01
CS (%) 16.6  2.4 21.6  3.6 <0.01
RS (%) 39.9  13.1 44.9  14.3 <0.04
RV parameters
RVEDA (cm2) 13.9  3.9 12.6  2.5 0.01
RVESA (cm2) 6.6  2.4 5.7  1.5 <0.01
RVFAC (%) 0.53  0.08 0.55  0.06 0.06
TAPSE (cm) 2.3  0.4 2.3  0.2 0.77
RVSP (mmHg) 25.3  7.8 15.6  6.7 <0.01
RV total longitudinal strain (%) 21.2  4.4 23.0  2.6 <0.01
Except where indicated otherwise, values are the mean  SD or n (%). A, peak late
diastolic velocity of mitral inﬂow; CS, circumferential strain; E, peak early diastolic
velocity of mitral inﬂow; e0 , early diastolic velocity at LV basal lateral segment; E/A
ratio, ratio of peak early diastolic velocity to late diastolic velocity of mitral inﬂow;
E/e0 , ratio of peak early diastolic velocity to early diastolic velocity at LV basal lateral
segment; LS, longitudinal strain; LV, left ventricular; RS, radial strain; RV, right
ventricular; RVEDA, right ventricular end-diastolic area; RVESA, right ventricular
end-systolic area; RVFAC, right ventricular fractional area change; RVSP, right
ventricular systolic pressure; TAPSE, tricuspid annular plane systolic excursion.
Table 4
Prospective echocardiography assessment in patients prior to and following liver
transplantation (LTx).
Pre-LTx
(n = 41)
Post-LTx
(n = 41)
p
Systolic blood pressure (mmHg) 120.0  15.7 125.0  15.3 0.08
Diastolic blood pressure (mmHg) 68.0  12.9 79.6  15.7 <0.01
Body mass index (kg/m2) 25.0  4.1 24.1  4.5 0.11
Creatinine (mg/dl) 87.6  37.5 97.4  24.2 0.11
LV conventional parameters
LV end-diastolic septal
thickness (cm)
1.1  0.2 1.2  0.2 0.03
LV end-diastolic diameter (cm) 4.8  0.6 4.4  0.5 <0.01
LV end-diastolic posterior
wall thickness (cm)
0.9  0.2 1.0  0.1 0.07
LV mass (g) 214.0  55.1 195.8  54.5 0.049
LV end diastolic volume (ml) 91.4  27.1 71.3  16.9 <0.01
LV end systolic volume (ml) 32.2  12.9 25.2  7.7 <0.01
LV ejection fraction (%) 66.1  4.6 65.2  4.7 0.30
Heart rate (beats/min) 71.5  15.1 70.5  11.0 0.67
LV diastolic function parameters
E (m/s) 0.83  0.21 0.75  0.14 0.04
A (m/s) 0.82  0.23 0.81  0.19 0.73
E/A ratio 1.08  0.38 0.97  0.27 0.06
LV diastolic function grade, n (%)
Normal 23 (56.1) 17 (41.4) 0.38
Mild 14 (34.1) 20 (48.8)
Moderate 4 (9.8) 4 (9.8)
Severe 0 (0) 0 (0)
E/e0 – lateral 7.2  2.1 6.8  2.0 0.30
LV strain analysis
LS (%) 18.5  2.6 20.8  2.0 <0.01
CS (%) 16.5  2.4 18.7  2.3 <0.01
RS (%) 39.9  13.2 41.4  8.6 0.83
RV parameters
RVEDA (cm2) 13.6  3.7 12.4  2.2 0.01
RVESA (cm2) 6.2  2.1 5.5  1.2 0.02
RVFAC (%) 0.55  0.06 0.55  0.05 0.76
TAPSE (cm) 2.3  0.3 2.2  0.2 0.11
RVSP (mmHg) 25.3  8.1 23.2  7.5 0.14
RV total longitudinal strain (%) 21.0  4.8 23.2  2.5 <0.01
A, peak late diastolic velocity of mitral inﬂow; CS, circumferential strain; E, peak
early diastolic velocity of mitral inﬂow; e0 , early diastolic velocity at LV basal
lateral segment; E/A ratio, ratio of peak early diastolic velocity to late diastolic
velocity of mitral inﬂow; E/e0 , ratio of peak early diastolic velocity to early
diastolic velocity at LV basal lateral segment; LS, longitudinal strain; LV, left
ventricular; RS, radial strain; RV, right ventricular; RVEDA, right ventricular
end-diastolic area; RVESA, right ventricular end-systolic area; RVFAC, right
ventricular fractional area change; RVSP, right ventricular systolic pressure;
TAPSE, tricuspid annular plane systolic excursion.
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systolic strains in all 3 orthogonal directions were impaired in
patients with cirrhosis compared with controls.
With reference to right heart echocardiography parameters,
patients with cirrhosis had a larger RV end-diastolic and end-
systolic area, and higher RVSP than controls. Importantly, patients
with cirrhosis had an impaired RV systolic strain, compared with
controls, despite similar conventional RV function as determined
by RVFAC and TAPSE.
Nonetheless patients with Child A, B, and C grade cirrhosis had a
similar global LV systolic longitudinal strain (17.7  2.4% vs.
18.9  2.8% vs. 19.0  2.5%; p = 0.09), circumferential strain
(16.0  2.5% vs. 16.6  2.4% vs. 17.0  2.3%; p = 0.23), radial strain
(37.9  13.7% vs. 40.2  12.2% vs. 39.9  13.1%; p = 0.62), and RV
systolic strain (19.7  4.7% vs. 21.8  3.7% vs. 21.7  4.5%;
p = 0.11).
Comparison of echocardiography parameters pre- and post-LTx
The comparison of pre and post-LTx echocardiography param-
eters in 41 patients is shown in Table 4. Following LTx, there was a
signiﬁcant reduction in LV dimension and volume, a lower LV
mass, and an improved LV global systolic longitudinal and
circumferential strain. There was also a reduced RV end-diastolic
and end-systolic area, and improved RV systolic strain. The change
in biventricular strain and dimension was nonetheless not related
to age, gender, and use of medications (p > 0.05).Prospective echocardiography parameters of patients without LTx
The comparison between baseline and follow-up echocardio-
graphic parameters in patients who did not undergo LTx is
presented in Table 5. The LV wall thickness and LV mass were
signiﬁcantly increased on follow-up echocardiography. No signiﬁ-
cant alteration to LV systolic and diastolic function and RV
parameters was noted. The change in LV wall thickness and LV
mass was nonetheless not related to age, gender, and use of
medications (p > 0.05).
Discussion
The present study demonstrates that patients with cirrhosis
have biventricular dilatation and impaired biventricular systolic
strain compared with controls. Importantly, patients with cirrhosis
following LTx had reduced biventricular dilatation and improved
biventricular systolic strain. For those who did not undergo LTx,
follow-up echocardiography demonstrated a progressive increase
in LV wall thickness and mass.
Table 5
Prospective echocardiography assessment in patients who did not receive LTx.
Baseline
(n = 26)
Follow up
(n = 26)
p
Systolic blood pressure (mmHg) 119.4  16.9 121.4  18.9 0.54
Diastolic blood pressure (mmHg) 72.6  10.7 75.5  13.1 0.20
Body mass index (kg/m2) 25.1  5.7 25.9  6.4 0.16
Creatinine (mg/dl) 90.3  28.5 91.6  31.6 0.78
LV conventional parameters
LV end-diastolic septal
thickness (cm)
1.0  0.2 1.2  0.1 <0.01
LV end-diastolic diameter (cm) 4.6  0.5 4.6  0.6 0.90
LV end-diastolic posterior
wall thickness (cm)
1.0  0.1 1.1  0.1 0.01
LV mass (g) 199.1  51.5 225.4  52.7 <0.01
LV end diastolic volume (ml) 88.2  21.1 85.7  32.6 0.53
LV end systolic volume (ml) 31.9  9.8 30.5  12.6 0.35
LV ejection fraction (%) 64.3  4.0 64.4  6.8 0.97
Heart rate (beats/min) 65.2  11.0 65.6  11.0 0.88
LV diastolic function parameters
E (m/s) 0.80  0.17 0.80  0.18 0.98
A (m/s) 0.74  0.29 0.77  0.21 0.29
E/A ratio 1.23  0.48 1.13  0.46 0.27
LV diastolic function grade, n (%)
Normal 15 (57.7) 14 (53.9) 0.99
Mild 9 (34.7) 10 (38.5)
Moderate 1 (3.8) 1 (3.8)
Severe 1 (3.8) 1 (3.8)
E/e0 – lateral 7.2  2.3 7.2  3.1 0.89
LV strain analysis
LS (%) 18.6  2.0 18.6  2.9 0.98
CS (%) 17.0  1.9 17.2  3.0 0.73
RS (%) 39.4  11.9 36.2  5.5 0.20
RV parameters
RVEDA (cm2) 13.1  4.0 13.3  3.5 0.86
RVESA (cm2) 6.3  2.1 6.5  1.8 0.55
RVFAC (%) 0.52  0.06 0.51  0.06 0.52
TAPSE (cm) 2.3  0.3 2.3  0.4 0.72
RVSP (mmHg) 24.2  6.3 24.1  6.7 0.94
RV total longitudinal strain (%) 21.7  3.9 21.6  4.0 0.96
A, peak late diastolic velocity of mitral inﬂow; CS, circumferential strain; E, peak
early diastolic velocity of mitral inﬂow; e0 , early diastolic velocity at LV basal
lateral segment; E/A ratio, ratio of peak early diastolic velocity to late diastolic
velocity of mitral inﬂow; E/e0 , ratio of peak early diastolic velocity to early
diastolic velocity at LV basal lateral segment; LS, longitudinal strain; LV, left
ventricular; RS, radial strain; RV, right ventricular; RVEDA, right ventricular
end-diastolic area; RVESA, right ventricular end-systolic area; RVFAC, right
ventricular fractional area change; RVSP, right ventricular systolic pressure;
TAPSE, tricuspid annular plane systolic excursion.
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with cirrhosis have LV hypertrophy [4,16] that results in diastolic
dysfunction [3,4,16] and has been conﬁrmed by our studies. In
contrast, resting LV systolic functional impairment is not apparent
as measured by conventional methods such as LV ejection fraction,
partly because of reduced afterload due to a low systemic vascular
resistance. Recently, 2D speckle-tracking strain analysis has been
proposed as a sensitive and accurate method to evaluate
subclinical systolic dysfunction in various groups of disease
[13,17,18]. It allows detection of LV dysfunction in three
orthogonal directions, namely longitudinal, circumferential, and
radial. The LV myocardial ﬁber architecture has a multilayer and
helical arrangement of myoﬁbers that forms the multi-dimen-
sional deformation of LV during each cardiac cycle. Longitudinal
direction deformation is usually the ﬁrst to be affected in early
diseases of the myocardium and is suggestive of subendocardial
disease. Circumferential and radial strain is affected relatively late
in the disease process and represents transmural damage
[19]. Using this technique, a recent study has demonstrated that
patients with cirrhosis have impaired LV systolic longitudinal
strain compared with controls, suggestive of subendocardial
dysfunction [5]. The present study extends this ﬁnding bydemonstrating LV systolic strain deformation in all three
orthogonal directions that indicate transmural disease involve-
ment of the myocardium in patients with cirrhosis.
RV function has now been recognized as an important predictor
of survival in patients with cardiac disease [20]. Recently, a study
of 216 patients who underwent LTx demonstrated that for RV
echocardiography parameters, the degree of tricuspid regurgita-
tion in particular was most associated with adverse outcome
[6]. This study thus highlighted the importance of assessment of RV
in patients with cirrhosis. A previous post-mortem analysis
revealed a high rate of RV chamber dilatation in approximately
one-third of patients with cirrhosis [21]. Similar to the ﬁndings of
the present study, others have demonstrated that patients with
cirrhosis have a larger RV dimension than controls when measured
by echocardiography [16,22,23]. In the present study, the RV
dimension is signiﬁcantly increased in patients with cirrhosis. This
could be explained by an increased venous return to the right heart
caused by the development of portosystemic collaterals to
counterbalance the increased intrahepatic vascular resistance to
portal blood ﬂow [24]. Further, pulmonary arterial pressure is
increased that may further contribute to enlargement of RV
dimension. Upon liver transplantation, both the portosystemic
shunt and pulmonary arterial pressure will be reduced that may
partly explain the reduction in RV dimension [25]. Future
prospective studies are nonetheless required to discern the
underlying mechanism for RV dimension reduction following
liver transplantation. Importantly, the present results provide
additional evidence that RV myocardial contractility, as evaluated
by systolic strain, is impaired in patients with cirrhosis compared
with controls. It is of note that although hepato-pulmonary
syndrome and pulmonary hypertension may adversely affect RV
myocardial function, these conditions were excluded in the current
population. As a result, the impaired RV function observed should
be related to cirrhosis per se and cannot be attributed to these
conditions.
Theoretically, LTx may reverse cirrhotic cardiomyopathy.
Indeed, a study involving 15 patients with cirrhosis showed a
reduction in LV mass 6–12 months following LTx [7]. This is
conﬁrmed by the present study. Nonetheless reversibility of
cardiac dysfunction following LTx has not been documented. By
including a larger study population and using an advanced
echocardiographic technique, the present study enables detection
of a reduced biventricular dilatation and improved biventricular
systolic strain following LTx. This ﬁnding provides ﬁrm evidence
that LTx can reverse biventricular remodeling and improve
myocardial function in patients with cirrhosis.
The 2005 World Congress of Gastroenterology in Montreal
working party has deﬁned cirrhotic cardiomyopathy as impaired
contractility with systolic and diastolic dysfunction together with
prolonged QT interval in the absence of other known causes of
cardiac disease [26]. Nonetheless the current guidelines and
recommendations do not comment on the progression of cirrhotic
cardiomyopathy. The present study is the ﬁrst to prospectively
demonstrate that in patients with cirrhosis awaiting LTx, a
signiﬁcant increase in LV wall thickness and LV mass is observed.
Of note, up to 46% of patients were of Child-Pugh Grade A and had a
low MELD score indicative of early stage liver cirrhosis; progres-
sion of LV mass nonetheless remained signiﬁcant. This further
suggests that cardiomyopathy can be progressive irrespective of
the severity of cirrhosis. Future studies that encompass different
stages of cirrhosis are warranted to validate the current ﬁnding.
Clinical implications
Previous studies have demonstrated that LV echocardiography
parameters such as LV hypertrophy [27] and diastolic function
Y. Chen et al. / Journal of Cardiology 67 (2016) 140–146 145[28–30] can predict outcome in patients with cirrhosis, although
others could not replicate these results [6,31]. In contrast, the right
heart is more sensitive to any alteration in preload and afterload
than the left heart [32]. Accordingly, accurate detection of cardiac
function, especially RV function, is key to risk stratify cardiac
complications for candidates awaiting LTx. The advent of advanced
2D speckle tracking derived strain analysis, as in the present study,
provides a sensitive and reliable method to accurately assess
biventricular function and predict outcomes in patients with
cirrhosis. Importantly, the present study demonstrated that LV
hypertrophy is progressive in patients with cirrhosis but can be
reversed upon LTx. The progressive nature of adverse LV
remodeling highlights the importance of regular assessment by
echocardiography to detect signiﬁcant changes to cardiac function
in candidates awaiting LTx. The rate of adverse progression and its
clinical signiﬁcance nonetheless require evaluation by a larger
study cohort.
Limitations
The present study did not perform invasive hemodynamic
measurements to assess for ventricular wall stress, cardiac output
and systemic vascular resistance and would require elaboration
from future studies. Further, the sequence of RV and LV dilatation
and dysfunction would require assessment by additional studies.
Patients with cirrhosis have prolonged QT interval that may
reverse upon liver transplantation [33]. Whether the reversal of QT
interval is related to biventricular dimension and function
improvement following liver transplantation would require
further evaluation. The present study did not include the
evaluation of clinical outcome. Future studies are therefore needed
to evaluate the prognostic value and to better deﬁne the frequency
of echocardiography assessment in patients with cirrhosis.
Furthermore, only 2-dimensional echocardiographic parameters
were used to evaluate both geometry and function. Novel 3-
dimensional echocardiography geometric assessment could be
used to conﬁrm the present ﬁndings. The majority of cases of
cirrhosis were due to viral hepatitis; future studies in patients with
other etiologies (for example alcoholic cirrhosis) will be required.
Conclusion
This study demonstrates that patients with cirrhosis had
biventricular dilatation and impaired biventricular function
measured by systolic strain analysis that is not apparent on
conventional echocardiographic assessment. Reduced biventricu-
lar dilatation and improved biventricular systolic function was
detected following LTx. For those who did not undergo LTx, a
signiﬁcant increase in LV mass was observed.
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